Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress

Stock Information for Keen Vision Acquisition Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Keen Vision Acquisition Corporation

Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy
Medera's Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of PLYA, LTRPA, MHLD, KVAC to Act Now
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction
STOCKHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - NHHS, KVAC, AMPS, AVTE

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.